FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297641> ?p ?o ?g. }

• W4286297641 endingPage "8054" @default.
• W4286297641 startingPage "8054" @default.
• W4286297641 abstract "8054 Background: The introduction of immunomodulatory agents, proteasome inhibitors, and autologous stem cell transplantation (ASCT) has improved outcomes for patients with multiple myeloma (MM), but those with high risk MM (HRMM) have a poor long-term prognosis. Herein we provide survival outcomes on the first randomized trial in newly diagnosed HRMM, S1211, to follow-up on the previously reported progression-free survival (PFS) (NCT01668719, Usmani SZ et al, Lancet Haem 2021). Methods: S1211 is a randomized phase II trial comparing 8 cycles of lenalidomide, bortezomib and dexamethasone (RVd) induction followed by dose-attenuated RVd maintenance until disease progression with or without elotuzumab (RVd-Elo). Stem cell collection was allowed, but ASCT was deferred until progression. HRMM was defined by one of the following: gene expression profiling high-risk (GEP hi ), t(14;16), t(14;20), del(17p), amplification 1q21, primary plasma cell leukemia (pPCL), or elevated serum LDH (> 2X ULN). Median PFS was the primary endpoint, using a one-sided stratified log-rank test at a one-sided significance level of 0.1. Secondary endpoints included overall response rate (ORR), adverse events (AE), serious adverse events (SAE) and OS. Response was assessed using the IMWG 2009 criteria. Results: S1211 enrolled 103 evaluable patients, RVd n=54, RVd-Elo n=49. 74% had ISS II/III, 48% amp1q21, 38% del(17p), 11% t(14;16), 9% GEP hi , 7% pPCL, 5% t(14;20) and 4% elevated LDH (17% >1 feature). With median follow-up of 72 months (mos.), no difference in median PFS was observed [RVd-Elo=29 mos., RVd= 34 mos., HR = 1.11 (80% CI=0.82, 1.49, p=0.66]. No difference in OS was observed [RVd-Elo = median not reached (NR), RVd= 68 mos., HR = 0.85 (80% CI: 0.59, 1.23), p-value = 0.58]. 76% pts had >Grade 3 AEs, no differences in the safety profile were observed. Amongst patients with gain/amp 1q21, median PFS was [RVd-Elo=31 mos., RVd= 37 mos., HR = 1.48 (80% CI= 0.95, 2.31), p=0.25], median OS was [RVd-Elo = 61 mos., RVd= 68 mos., HR = 1.23 (80% CI: 0.72, 2.10), p-value = 0.63]. In patients with del(17p), median PFS was RVd-Elo=41 mos., RVd= 30 mos.[HR = 0.98 (80% CI= 0.60, 1.58), p=0.95], median OS RVd-Elo = NR, RVd= 72 mos., [HR = 0.77 (80% CI: 0.40, 1.48), p-value = 0.61]. Conclusions: In the first randomized HRMM study reported to date, the addition of Elo to RVd induction and maintenance did not improve PFS and OS with a median follow-up of 6 years. Although the median PFS for Del17p subgroup on RVd-Elo arm is higher than RVd, it did not achieve statistical significance. The PFS and OS observed for gain/amp 1q21 and del17p in the RVd control arm may serve as important benchmarks for future enrichment design HRMM clinical trials. The PFS and OS in both arms of the study exceeded the original statistical assumptions and support the role for PI/IMiD combination induction/maintenance therapy for this population. Clinical trial information: NCT01668719." @default.
• W4286297641 created "2022-07-21" @default.
• W4286297641 creator A5009378735 @default.
• W4286297641 creator A5024461673 @default.
• W4286297641 creator A5026109406 @default.
• W4286297641 creator A5034791164 @default.
• W4286297641 creator A5035289098 @default.
• W4286297641 creator A5038235561 @default.
• W4286297641 creator A5040237587 @default.
• W4286297641 creator A5042432109 @default.
• W4286297641 creator A5043526996 @default.
• W4286297641 creator A5044589378 @default.
• W4286297641 creator A5058127611 @default.
• W4286297641 creator A5071438752 @default.
• W4286297641 creator A5072484302 @default.
• W4286297641 creator A5087265191 @default.
• W4286297641 creator A5088292582 @default.
• W4286297641 creator A5088696429 @default.
• W4286297641 date "2022-06-01" @default.
• W4286297641 modified "2023-10-01" @default.
• W4286297641 title "Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211)." @default.
• W4286297641 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.8054" @default.
• W4286297641 hasPublicationYear "2022" @default.
• W4286297641 type Work @default.
• W4286297641 citedByCount "2" @default.
• W4286297641 countsByYear W42862976412023 @default.
• W4286297641 crossrefType "journal-article" @default.
• W4286297641 hasAuthorship W4286297641A5009378735 @default.
• W4286297641 hasAuthorship W4286297641A5024461673 @default.
• W4286297641 hasAuthorship W4286297641A5026109406 @default.
• W4286297641 hasAuthorship W4286297641A5034791164 @default.
• W4286297641 hasAuthorship W4286297641A5035289098 @default.
• W4286297641 hasAuthorship W4286297641A5038235561 @default.
• W4286297641 hasAuthorship W4286297641A5040237587 @default.
• W4286297641 hasAuthorship W4286297641A5042432109 @default.
• W4286297641 hasAuthorship W4286297641A5043526996 @default.
• W4286297641 hasAuthorship W4286297641A5044589378 @default.
• W4286297641 hasAuthorship W4286297641A5058127611 @default.
• W4286297641 hasAuthorship W4286297641A5071438752 @default.
• W4286297641 hasAuthorship W4286297641A5072484302 @default.
• W4286297641 hasAuthorship W4286297641A5087265191 @default.
• W4286297641 hasAuthorship W4286297641A5088292582 @default.
• W4286297641 hasAuthorship W4286297641A5088696429 @default.
• W4286297641 hasConcept C126322002 @default.
• W4286297641 hasConcept C141071460 @default.
• W4286297641 hasConcept C143998085 @default.
• W4286297641 hasConcept C168563851 @default.
• W4286297641 hasConcept C197934379 @default.
• W4286297641 hasConcept C203092338 @default.
• W4286297641 hasConcept C2776063141 @default.
• W4286297641 hasConcept C2776364478 @default.
• W4286297641 hasConcept C2776694085 @default.
• W4286297641 hasConcept C2777478702 @default.
• W4286297641 hasConcept C2779050716 @default.
• W4286297641 hasConcept C2780401358 @default.
• W4286297641 hasConcept C2780739268 @default.
• W4286297641 hasConcept C2911091166 @default.
• W4286297641 hasConcept C71924100 @default.
• W4286297641 hasConcept C90924648 @default.
• W4286297641 hasConceptScore W4286297641C126322002 @default.
• W4286297641 hasConceptScore W4286297641C141071460 @default.
• W4286297641 hasConceptScore W4286297641C143998085 @default.
• W4286297641 hasConceptScore W4286297641C168563851 @default.
• W4286297641 hasConceptScore W4286297641C197934379 @default.
• W4286297641 hasConceptScore W4286297641C203092338 @default.
• W4286297641 hasConceptScore W4286297641C2776063141 @default.
• W4286297641 hasConceptScore W4286297641C2776364478 @default.
• W4286297641 hasConceptScore W4286297641C2776694085 @default.
• W4286297641 hasConceptScore W4286297641C2777478702 @default.
• W4286297641 hasConceptScore W4286297641C2779050716 @default.
• W4286297641 hasConceptScore W4286297641C2780401358 @default.
• W4286297641 hasConceptScore W4286297641C2780739268 @default.
• W4286297641 hasConceptScore W4286297641C2911091166 @default.
• W4286297641 hasConceptScore W4286297641C71924100 @default.
• W4286297641 hasConceptScore W4286297641C90924648 @default.
• W4286297641 hasFunder F4320332161 @default.
• W4286297641 hasIssue "16_suppl" @default.
• W4286297641 hasLocation W42862976411 @default.
• W4286297641 hasOpenAccess W4286297641 @default.
• W4286297641 hasPrimaryLocation W42862976411 @default.
• W4286297641 hasRelatedWork W2067463209 @default.
• W4286297641 hasRelatedWork W2470933183 @default.
• W4286297641 hasRelatedWork W2604776612 @default.
• W4286297641 hasRelatedWork W2884725265 @default.
• W4286297641 hasRelatedWork W2913361626 @default.
• W4286297641 hasRelatedWork W2981018427 @default.
• W4286297641 hasRelatedWork W3025827814 @default.
• W4286297641 hasRelatedWork W37180177 @default.
• W4286297641 hasRelatedWork W4206235322 @default.
• W4286297641 hasRelatedWork W4362657418 @default.
• W4286297641 hasVolume "40" @default.
• W4286297641 isParatext "false" @default.
• W4286297641 isRetracted "false" @default.
• W4286297641 workType "article" @default.